β遮断薬の世界市場レポート 2025年

β遮断薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.3%で131億1,000万米ドルに成長します。予測期間の成長は、心血管疾患の流行、心不全への応用拡大、併用療法、高血圧ガイドラインの重視、新規適応の探求などに起因すると考えられます。予測期間における主な動向には、不安な状況やパフォーマンスでの応用、潜在的な神経保護効果、個別化治療アプローチ、ジェネリック医薬品の影響、デジタルヘルスプラットフォームとの統合などがあります。

心血管疾患の有病率の増加がβ遮断薬市場の成長を牽引すると予測されます。心血管疾患（CVD）には、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。このCVD罹患率の増加は、主に不健康な食生活、座りがちなライフスタイル、運動不足、タバコの使用、肥満に起因しています。β遮断薬は、心臓機能や血液循環に様々な有益な効果をもたらし、心血管疾患の減少に重要な役割を果たします。その結果、心血管疾患患者の増加がβ遮断薬市場の拡大に拍車をかけています。例えば、2024年9月に英国を拠点とする循環器研究慈善団体であるBritish Heart Foundationのデータから、英国では約760万人が心臓および循環器疾患に罹患していることが明らかになりました。その内訳は、男性約400万人、女性約360万人です。これらの病気は英国における全死亡者の約27％を占め、毎年17万人以上、1日当たり約480人が死亡しており、3分に1人が死亡している計算になります。したがって、心血管疾患の発生率の増加は、β遮断薬市場の成長に貢献します。

緑内障の有病率の高まりは、β遮断薬市場の拡大を後押しします。緑内障は、視覚情報を脳に伝達する視神経を損傷することで、視力障害や失明の可能性をもたらす眼疾患群です。β遮断薬は眼圧（IOP）を下げることにより、緑内障の管理に極めて重要な役割を果たしています。そのメカニズムは、眼内液である房水の産生を減少させ、眼圧を緩和することにあります。例えば、BrightFocus Foundationが2022年10月に報告したように、300万人以上の米国人が緑内障に罹患しており、40歳以上の270万人が最も有病率の高い開放隅角緑内障に罹患しています。世界全体では8,000万人が緑内障に罹患しており、この数字は2040年までに1億1,100万人を超えると予想されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のβ遮断薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のβ遮断薬市場：成長率分析
• 世界のβ遮断薬市場の実績：規模と成長、2019～2024年
• 世界のβ遮断薬市場の予測：規模と成長、2024～2029年、2034年
• 世界のβ遮断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のβ遮断薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非選択的薬剤
• 選択的薬剤
• 世界のβ遮断薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 狭心症
• 心不全
• 高血圧
• その他
• 世界のβ遮断薬市場：薬物別、実績と予測、2019～2024年、2024～2029年、2034年
• ベタキソロール
• アセブトロール
• エスモロール
• その他
• 世界のβ遮断薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のβ遮断薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 心臓疾患
• 高血圧
• 緑内障
• その他
• 世界のβ遮断薬市場：非選択的薬剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プロプラノロール
• ナドロール
• チモロール
• 世界のβ遮断薬市場：選択的薬剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アテノロール
• メトプロロール
• ビソプロロール
• ネビボロール

第7章 地域別・国別分析

• 世界のβ遮断薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のβ遮断薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• β遮断薬市場：競合情勢
• β遮断薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb Company
• Bayer AG
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• Abbott Laboratories
• Eagle Pharmaceuticals Inc.
• Neon Healthcare Ltd.
• Midas Pharma GmbH
• Global Calcium PVT. LTD.
• AbbVie Inc.
• Mylan N.V.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• β遮断薬市場2029年：新たな機会を提供する国
• β遮断薬市場2029年：新たな機会を提供するセグメント
• β遮断薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Beta blockers, also recognized as beta-adrenergic blocking agents, constitute a medication class widely employed in managing diverse cardiovascular conditions by mitigating heart activity. Their common prescription aims at regulating blood pressure, addressing angina, managing heart failure, and addressing certain cardiac rhythm irregularities.

Within the beta blockers spectrum, two primary types include non-selective agents and selective agents. Non-selective agents within the beta-blockers market encompass medications that impede or obstruct beta-adrenergic receptors' effects without a specific affinity toward any particular subtype. These agents serve to regulate various physiological functions encompassing heart rate, blood pressure, bronchial smooth muscle tone, and peripheral vascular resistance. Their use spans across conditions such as angina pectoris, heart failure, high blood pressure, and other ailments, often managed through medications such as betaxolol, acebutolol, esmolol, among others. These drugs are available through hospital pharmacies, retail outlets, and online platforms, catering to the treatment of cardiac diseases, hypertension, glaucoma, and related conditions.

The beta blockers market research report is one of a series of new reports from The Business Research Company that provides beta blockers market statistics, including beta blockers industry global market size, regional shares, competitors with a beta blockers market share, detailed beta blockers market segments, market trends, and opportunities, and any further data you may need to thrive in the beta blockers industry. This beta blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beta blockers market size has grown strongly in recent years. It will grow from$9.67 billion in 2024 to $10.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to hypertension management, treatment of cardiovascular diseases, post-myocardial infarction care, migraine prophylaxis, and management of anxiety and tremors

The beta blockers market size is expected to see strong growth in the next few years. It will grow to $13.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the prevalence of cardiovascular diseases, expanded applications in heart failure, combination therapies, focus on hypertension guidelines and exploration of novel indications. Major trends in the forecast period include application in anxiety and performance situations, potential neuroprotective effects, individualized treatment approaches, impact of generic versions, and integration with digital health platforms.

The increasing prevalence of cardiovascular diseases is projected to drive the growth of the beta blockers market. Cardiovascular diseases (CVDs) encompass a range of disorders that impact the heart and blood vessels. This rise in CVD incidence is primarily attributed to unhealthy diets, sedentary lifestyles, lack of physical activity, tobacco use, and obesity. Beta blockers can play a significant role in reducing cardiovascular cases by providing various beneficial effects on heart function and blood circulation. Consequently, the growing number of cardiovascular disease cases is fueling the expansion of the beta blockers market. For example, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that around 7.6 million people in the UK are affected by heart and circulatory diseases. This includes approximately 4 million males and 3.6 million females. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 fatalities each year, or roughly 480 deaths daily, which translates to one death every three minutes. Therefore, the rising incidence of cardiovascular diseases will contribute to the growth of the beta blockers market.

The mounting prevalence of glaucoma is poised to drive the beta blockers market's expansion. Glaucoma comprises a group of eye conditions leading to vision impairment and potential blindness by harming the optic nerve responsible for transmitting visual information to the brain. Beta blockers play a pivotal role in managing glaucoma by reducing intraocular pressure (IOP). Their mechanism involves diminishing the production of aqueous humor, the eye's internal fluid, thereby alleviating the pressure within the eye. For instance, as reported by the BrightFocus Foundation in October 2022, over three million Americans are affected by glaucoma, with 2.7 million individuals aged 40 and older experiencing its most prevalent form, open-angle glaucoma. Globally, 80 million people are afflicted by glaucoma, a figure anticipated to surpass 111 million by 2040.

Key players in the beta-blockers market are concentrating on developing innovative products, such as cardioselective beta-blockers and ultra-short-acting beta-blockers, to enhance patient outcomes related to cardiovascular health. Cardioselective beta-blockers specifically target B1 receptors in the heart, which helps reduce respiratory side effects and improves efficacy through advanced formulations. Ultra-short-acting beta-blockers, such as Landiolol, offer a rapid onset and offset of action, making them particularly suitable for acute care environments and critically ill patients who require swift heart rate management. For example, in January 2022, Eagle Pharmaceuticals, Inc., a pharmaceutical company based in the U.S., announced the submission of a new drug application (NDA) for Landiolol, a beta-1 adrenergic blocker intended for the short-term reduction of ventricular rates in patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter. This initiative aims to introduce Landiolol to the U.S. market, thereby expanding Eagle Pharmaceuticals' footprint in acute care and ultimately enhancing treatment options for patients with tachycardia.

Leading companies in the beta blockers sector are prioritizing the introduction of advanced beta blocking agents for severe hypertension management and blood pressure reduction, aiming to gain a competitive advantage. Beta blockers play a crucial role in addressing severe hypertension and lowering blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, thus reducing peripheral resistance and safeguarding the heart from reflex sympathetic drive. For instance, in March 2023, Hikma Pharmaceuticals PLC launched Labetalol Hydrochloride (Labetalol HCl) Injection, USP, in prefilled syringe (PFS) form in the US for treating severe hypertension and reducing blood pressure. Labetalol combines selective alpha1-adrenergic blocking and nonselective beta-adrenergic blocking activities in a single substance, functioning primarily by blocking peripheral arteriolar alpha-adrenoceptors to decrease resistance and lower blood pressure.

In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed sum. This acquisition is intended to double Marksans Pharma's production capacity in India, solidifying its position as a prominent low-cost manufacturer and enabling it to effectively meet the increasing demands of its customer base. Teva Pharmaceutical Industries Ltd., based in Israel, is a multinational pharmaceutical company involved in the development, manufacturing, and commercialization of generic and specialty medications.

Major companies operating in the beta blockers market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca plc, Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, Global Calcium PVT. LTD., AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Aspen Pharmacare Holdings Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Sandoz International GmbH, Wockhardt Ltd., Endo Pharmaceuticals Inc., Apotex Inc.

North America was the largest region in the beta blockers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global beta-blockers market report during the forecast period. The regions covered in the beta blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the beta blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The beta blockers market consists of sales of sales of metoprolol, nebivolol, timolol, and labetalol. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Beta Blockers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on beta blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for beta blockers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The beta blockers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-selective Agents; Selective Agents
• 2) By Indication: Angina Pectoris; Heart Failure; High Blood Pressure; Other Indications
• 3) By Drugs: Betaxolol; Acebutolol; Esmolol; Other Drugs
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By Application: Cardiac Diseases; Hypertension; Glaucoma; Other Applications
• Subsegments:
• 1) By Non-Selective Agents: Propranolol; Nadolol; Timolol
• 2) By Selective Agents: Atenolol; Metoprolol; Bisoprolol; Nebivolol
• Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca plc; Johnson and Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Beta Blockers Market Characteristics

3. Beta Blockers Market Trends And Strategies

4. Beta Blockers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Beta Blockers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Beta Blockers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Beta Blockers Market Growth Rate Analysis
• 5.4. Global Beta Blockers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Beta Blockers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Beta Blockers Total Addressable Market (TAM)

6. Beta Blockers Market Segmentation

• 6.1. Global Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-selective Agents
• Selective Agents
• 6.2. Global Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angina Pectoris
• Heart Failure
• High Blood Pressure
• Other Indications
• 6.3. Global Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Betaxolol
• Acebutolol
• Esmolol
• Other Drugs
• 6.4. Global Beta Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Diseases
• Hypertension
• Glaucoma
• Other Applications
• 6.6. Global Beta Blockers Market, Sub-Segmentation Of Non-Selective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Propranolol
• Nadolol
• Timolol
• 6.7. Global Beta Blockers Market, Sub-Segmentation Of Selective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atenolol
• Metoprolol
• Bisoprolol
• Nebivolol

7. Beta Blockers Market Regional And Country Analysis

• 7.1. Global Beta Blockers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Beta Blockers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Beta Blockers Market

• 8.1. Asia-Pacific Beta Blockers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Beta Blockers Market

• 9.1. China Beta Blockers Market Overview
• 9.2. China Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Beta Blockers Market

• 10.1. India Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Beta Blockers Market

• 11.1. Japan Beta Blockers Market Overview
• 11.2. Japan Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Beta Blockers Market

• 12.1. Australia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Beta Blockers Market

• 13.1. Indonesia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Beta Blockers Market

• 14.1. South Korea Beta Blockers Market Overview
• 14.2. South Korea Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Beta Blockers Market

• 15.1. Western Europe Beta Blockers Market Overview
• 15.2. Western Europe Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Beta Blockers Market

• 16.1. UK Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Beta Blockers Market

• 17.1. Germany Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Beta Blockers Market

• 18.1. France Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Beta Blockers Market

• 19.1. Italy Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Beta Blockers Market

• 20.1. Spain Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Beta Blockers Market

• 21.1. Eastern Europe Beta Blockers Market Overview
• 21.2. Eastern Europe Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Beta Blockers Market

• 22.1. Russia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Beta Blockers Market

• 23.1. North America Beta Blockers Market Overview
• 23.2. North America Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Beta Blockers Market

• 24.1. USA Beta Blockers Market Overview
• 24.2. USA Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Beta Blockers Market

• 25.1. Canada Beta Blockers Market Overview
• 25.2. Canada Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Beta Blockers Market

• 26.1. South America Beta Blockers Market Overview
• 26.2. South America Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Beta Blockers Market

• 27.1. Brazil Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Beta Blockers Market

• 28.1. Middle East Beta Blockers Market Overview
• 28.2. Middle East Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Beta Blockers Market

• 29.1. Africa Beta Blockers Market Overview
• 29.2. Africa Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Beta Blockers Market Competitive Landscape And Company Profiles

• 30.1. Beta Blockers Market Competitive Landscape
• 30.2. Beta Blockers Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Beta Blockers Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb Company
• 31.4. Bayer AG
• 31.5. GlaxoSmithKline plc
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Amneal Pharmaceuticals LLC
• 31.9. Abbott Laboratories
• 31.10. Eagle Pharmaceuticals Inc.
• 31.11. Neon Healthcare Ltd.
• 31.12. Midas Pharma GmbH
• 31.13. Global Calcium PVT. LTD.
• 31.14. AbbVie Inc.
• 31.15. Mylan N.V.

32. Global Beta Blockers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Beta Blockers Market

34. Recent Developments In The Beta Blockers Market

35. Beta Blockers Market High Potential Countries, Segments and Strategies

• 35.1 Beta Blockers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Beta Blockers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Beta Blockers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer